Hengrui Medicine will soon apply for another ophthalmic drug

Recently, Hengrui Medicine announced that SHR8058 eye drops for the treatment of meibomian gland dysfunction-related dry eye disease is a multicenter, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301).
The superiority standard will be submitted to CDE for pre-market communication applications in the near future
.
According to data, SHR8058 eye drops are NOV03 (perfluorohexyl octane) introduced by Hengrui Medicine from Novaliq GmbH.
It can treat meibomian gland dysfunction by forming a stable envelope on the surface of the eye and preventing excessive tears from evaporating.
Related evaporative dry eye syndrome
.
At the end of last year, Hengrui Medicine received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, approving the company's SHR8058 eye drops to carry out clinical trials for dry eye related to meibomian gland dysfunction
.
It is worth noting that, in addition to SHR8058 eye drops, the tafluprost eye drops declared by Chengdu Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of Hengrui Pharmaceuticals, has been approved for marketing, becoming the first imitation of the product
.
According to the author’s understanding, tafluprost is a prostaglandin analogue, a selective FP prostaglandin receptor agonist, which can reduce intraocular pressure by increasing the uveoscleral aqueous humor outflow, and is used to reduce open-angle type Elevated intraocular pressure in patients with glaucoma and ocular hypertension
.
At present, no generic medicine of tafluprostaglandin eye drops has been approved to be marketed in China.
In addition, there are fewer manufacturers of this product, with only two companies, Shengdi Pharmaceutical and Sichuan Kelun
.
It is understood that, in fact, Hengrui Medicine has been continuously transforming into an innovative pharmaceutical company in recent years, and its layout in ophthalmology has been accelerating
.
In addition to the above drugs, as early as 2001, Hengrui Medicine invested 9 million yuan in Chengdu Hengrui to develop businesses including the production of eye drops
.
The analysis believes that the main reason why Hengrui Medicine continues to increase its weight in the ophthalmology field is mainly because it is optimistic about its market development prospects
.
It is reported that in recent years, with the deepening of aging in my country, increasing work intensity, and changing life>
.
The industry predicts that by 2025, the size of China's ophthalmology market may exceed 310 billion at least
.
Therefore, in the context of the rapid growth trend in the current ophthalmology market, except for Hengrui Medicine, a large number of companies are accelerating their entry into this market
.
It is reported that many companies have announced new breakthroughs in this field since the beginning of this year
.
For example, on October 29, Osaikang issued an announcement stating that the company’s application for a clinical trial of the new drug ASKG712 for injection has been accepted.
) And RVO-ME (macular edema secondary to branch retinal vein occlusion) and so on
.
It is understood that ASKG712 for injection is a dual-targeting anti-VEGF-A humanized monoclonal antibody-Ang-2 inhibitory peptide fusion protein with independent intellectual property rights developed by the company
.
In general, China's eye disease diagnosis and treatment market has a bright future
.
As more and more companies enter the market, related drugs will continue to emerge, but it should be noted that market competition will also intensify
.
In the future, companies that have advantages in specialty promotion may have higher voice and channel advantages, and will usher in more development opportunities
.